Article Contents ::
- 1 Details About Generic Salt :: Venlafax
- 2 Main Medicine Class::
- 3
(VEN-luh-fax-EEN)
Effexor
Tablets
25 mg
Tablets
37.5 mg
Tablets
50 mg
Tablets
75 mg
Tablets
100 mg
Effexor XR
Capsules, extended-release
37.5 mg
Capsules, extended-release
75 mg
Capsules, extended-release
150 mg
Class: Antidepressant
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
PATIENT CARE CONSIDERATIONS
Administration/Storage
Administer with meals.
Store at room temperature in tight container.
Assessment/Interventions
Obtain patient history, including drug history and any known allergies.
Establish baseline weight.
Establish baseline serum cholesterol level.
After 4 to 6 wk of therapy, reevaluate long-term usefulness.
Monitor BP at least twice a week.
OVERDOSAGE: SIGNS & SYMPTOMS
Somnolence, sinus tachycardia
Patient/Family Education
Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
Tell patient to report any rash or hives.
Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Venlafax
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drugs Class ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Indications for Drugs ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Dose ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Contraindication ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Precautions ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Side Effects ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Mode of Action ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Interactions ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Drug Assesment ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Storage/Management ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Drug Notes ::
| (VEN-luh-fax-EEN) |
| Effexor |
| Tablets |
| 25 mg |
| Tablets |
| 37.5 mg |
| Tablets |
| 50 mg |
| Tablets |
| 75 mg |
| Tablets |
| 100 mg |
| Effexor XR |
| Capsules, extended-release |
| 37.5 mg |
| Capsules, extended-release |
| 75 mg |
| Capsules, extended-release |
| 150 mg |
| Class: Antidepressant |
Action Potentiates norepinephrine, serotonin, and dopamine neurotransmitter activity in CNS.
Indications Treatment of depression; generalized anxiety disorder (venlafaxine ER).
Contraindications Concomitant use with MAOIs.
Route/Dosage
Depression
ADULTS (immediate-release): PO 75 mg/day in 2 or 3 divided doses; titrate to clinical effect, adding up to 75 mg/day at intervals of ³ 4 days (max, 375 mg/day).
ADULTS (extended-release): PO 75 mg/day administered in single dose either in morning or evening at approximately same time each day. Make dose increases in increments of up to 75 mg/day as needed and at intervals of ³ 4 days.
Generalized Anxiety Disorder
ADULTS (extended-release): PO The usual dosage is 75 to 225 mg/day. Some patients may need to start with 37.5 mg/day to avoid overstimulation.
Interactions
Desipramine, Haloperidol: Plasma levels of these drugs may be elevated by venlavaxine, increasing the risk of adverse effects. MAOIs: MAOIs have produced serious, even fatal, reactions when given concomitantly with venlafaxine. Do not use venlafaxine together with MAOIs or within 14 days of MAOI use. Wait ³ 7 days after stopping venlafaxine before using MAOI. St. John’s Wort: Increased sedative-hypnotic effects may occur. Sibutramine, Sumatriptan, Trazodone: A “serotinin syndrome,” including irritability, increased muscle tone, shivering, myoclonus, and altered consciousness may occur.
Lab Test Interferences None well documented.
Adverse Reactions CARDIOVASCULAR: Hypertension; migraine; vasodilation; tachycardia; postural hypotension. CNS: Insomnia; somnolence; anxiety; headache; dizziness; nervousness; tremor; asthenia; abnormal dreams; hypertonia; paresthesia; agitation; confusion; abnormal thinking; depersonalization; twitching. DERMATOLOGIC: Sweating; rash; pruritus. EENT: Blurred vision; taste perversion; tinnitus; mydriasis. GI: Nausea; anorexia; dry mouth; constipation; dysphagia; diarrhea; vomiting; dyspepsia; flatulence; weight loss. GU: Abnormal ejaculation or orgasm; dysuria; hematuria; increased BUN; vaginitis; decreased libido; urinary retention; impotence; urinary frequency; anorgasmia (female); impaired urination; orgasm disturbance; menstrual disorder. HEMATOLOGIC: Ecchymosis. HEPATIC: Increased LFT results and bilirubin. METABOLIC: Peripheral edema; weight gain. RESPIRATORY: Dyspnea. OTHER: Pharyngitis; infection; chills; chest pain; trauma; yawn.
Precautions
Pregnancy: Category C. Lactation: Excreted in breast milk. CHILDREN: Safety and efficacy in patients < 18 yr not established. Elderly: Take extra care when increasing dose in elderly patients. Special Risk Patients: Use drug with caution in patients with history of seizure, mania, suicidal tendencies, drug abuse, or dependence. Hepatic or Renal Impairment: Reduction of dose may be necessary. Use drug with caution. Hypertension: Regular monitoring of BP is recommended. Venlafaxine is associated with sustained but small increases in BP (usually associated with doses > 300 mg/day). Discontinuation: After 1 wk of therapy, dosage requires tapering if discontinuing; after 6 wk of treatment, taper over 2-wk period.
|
PATIENT CARE CONSIDERATIONS |
|
Administration/Storage
- Administer with meals.
- Store at room temperature in tight container.
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Establish baseline weight.
- Establish baseline serum cholesterol level.
- After 4 to 6 wk of therapy, reevaluate long-term usefulness.
- Monitor BP at least twice a week.
| OVERDOSAGE: SIGNS & SYMPTOMS |
| |
Somnolence, sinus tachycardia |
|
Patient/Family Education
- Advise patient to avoid intake of alcoholic beverages and other CNS depressants.
- Tell patient to report any rash or hives.
- Advise patient to report to health care provider any other prescription or otc drugs that may be taken.
- Advise patient to take sips of water frequently, to suck on ice chips or sugarless hard candy, or sugarless chewing gum if dry mouth occurs.
- Instruct patient to use caution when driving or performing other tasks that require mental alertness or coordination.
- Advise patient to avoid prolonged exposure to sunlight or sunlamps or wear protective clothing; photosensitivity may occur.
- Advise patients to notify health care provider if pregnant, intending to become pregnant during therapy, or breastfeeding.
–>
Disclaimer ::
The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
